Recent studies have converged on the overlap of GLP-1|GIP|GCGR stimulant therapies and dopamine signaling. While GLP stimulators are commonly employed for managing type 2 diabetes, their potential impacts on reinforcement circuits, specifically influenced by DA systems, are receiving substantial focus. This paper provides a concise assessment of av